Insulet (PODD) EBITDA Margin Growth (3y) (2013 - 2026)
Insulet (PODD) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | -201.00 |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 586.00 |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 78.00 |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 736.00 |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 887.00 |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 963.00 |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 212.00 |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 535.00 |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 244.00 |
| 10 | Insulet | 10.18 Bn | 9.64 Bn | 562.60 Mn | 833.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 833.00 |
| Mar 31, 2026 | 829.00 |
| Dec 31, 2025 | 1,231.00 |
| Sep 30, 2025 | 1,581.00 |
| Jun 30, 2025 | 2,757.00 |
| Mar 31, 2025 | 278.00 |
| Dec 31, 2024 | 214.00 |
| Sep 30, 2024 | 333.00 |
| Jun 30, 2024 | 104.00 |
| Mar 31, 2024 | 642.00 |
| Dec 31, 2023 | 2,386.00 |
| Sep 30, 2023 | 249.00 |
| Jun 30, 2023 | -431.00 |
| Mar 31, 2023 | 395.00 |
| Dec 31, 2022 | -229.00 |
| Sep 30, 2022 | -800.00 |
| Jun 30, 2022 | -1,321.00 |
| Mar 31, 2022 | 826.00 |
| Dec 31, 2021 | 631.00 |
| Sep 30, 2021 | 833.00 |